Treatment options for patients relapsing after alloHSCT are limited.
Effectiveness of azacitidine was analyzed for prevention and treatment of relapse.
Azacitidine was ineffective in hematologic relapse.
Azacitidine seems to be a promising drug for preemptive and maintenance treatment.